NEW YORK (GenomeWeb News) – MolecularMD said today it has secured the rights to commercialize IP surrounding fibroblast growth factor receptor 2 activating mutations for diagnostic, prognostic, and predictive purposes in human endometrial cancer.

Rights to the IP are jointly held by Washington University in St. Louis and the Translational Genomics Research Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.

Adam Rutherford discusses genetic genealogy at the Guardian.

Portions of the US 21st Century Cures Act are raising some safety concerns.

David Dobbs writes at Buzzfeed that genomics has delivered little on its promises.